Camber Capital Management’s Biogen BIIB Stock Holding History

Camber Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-400,000	Closed	-$86.3M	–	38
2024 Q1	$86.3M	Buy	+400,000	New	+$93.7M	2.11%	16
2022 Q4	–	Sell	-200,000	Closed	-$53.4M	–	40
2022 Q3	$53.4M	Buy	200,000 +75,000	+60%	+$15.9M	1.64%	22
2022 Q2	$25.5M	Buy	+125,000	New	+$25.6M	1.11%	23
2022 Q1	–	Sell	-250,000	Closed	-$60M	–	39
2021 Q4	$60M	Buy	250,000 +175,000	+233%	+$45M	2.06%	22
2021 Q3	$21.2M	Buy	+75,000	New	+$24.6M	0.65%	35
2021 Q1	–	Sell	-200,000	Closed	-$49M	–	36
2020 Q4	$49M	Buy	+200,000	New	+$51.6M	1.72%	19
2020 Q2	–	Sell	-200,000	Closed	-$63.3M	–	32
2020 Q1	$63.3M	Sell	200,000 -150,000	-43%	-$45.5M	3.78%	12
2019 Q4	$104M	Hold	350,000	–	–	5.29%	3
2019 Q3	$81.5M	Buy	+350,000	New	+$81.5M	4.29%	8
2019 Q2	–	Sell	-400,000	Closed	-$94.6M	–	32
2019 Q1	$94.6M	Buy	400,000 +150,000	+60%	+$47.2M	4.71%	6
2018 Q4	$75.2M	Sell	250,000 -50,000	-17%	-$16M	3.57%	11
2018 Q3	$106M	Sell	300,000 -150,000	-33%	-$51.6M	4.54%	7
2018 Q2	$131M	Sell	450,000 -65,000	-13%	-$18.3M	5.03%	4
2018 Q1	$141M	Buy	+515,000	New	+$160M	6.92%	4
2017 Q3	–	Sell	-100,000	Closed	-$27.1M	–	24
2017 Q2	$27.1M	Buy	+100,000	New	+$26.4M	1.32%	22
2017 Q1	–	Sell	-175,000	Closed	-$49.6M	–	34
2016 Q4	$49.6M	Buy	+175,000	New	+$51.9M	2.58%	19
2016 Q3	–	Sell	-275,000	Closed	-$66.5M	–	38
2016 Q2	$66.5M	Buy	275,000 +100,000	+57%	+$26.4M	3.21%	8
2016 Q1	$45.6M	Buy	+175,000	New	+$46.2M	2.67%	17

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Camber Capital Management's BIIB Position: Q2 2024 in Review

Camber Capital Management sold out of Biogen (BIIB) in Q2 2024, closing a stake of 400,000 shares — an estimated $86.3M sold.

Camber Capital Management first reported a position in BIIB in Q1 2016 and held it in 18 quarters. The position peaked at $141M in Q1 2018. 944 funds tracked by Wall St. Rank hold BIIB as of Q2 2024.

Camber Capital Management reported no remaining Biogen position as of Q2 2024 after selling out during the quarter.
Camber Capital Management sold 400,000 Biogen shares in Q2 2024, an estimated $86.3M.
Camber Capital Management first reported a position in Biogen in Q1 2016 and held it in 18 quarters.
Camber Capital Management's Biogen position peaked at $141M in Q1 2018.
944 funds tracked by Wall St. Rank held Biogen as of Q2 2024.

Based on Camber Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.